Markus Eckstein @Markuseckstein3 Twitter profile

Pinned Tweet

Markus Eckstein

3 months

🌶️🌡️Summary of my uropathology for urologists and oncologists series! 👉check it out! and retweet if you like! @urotoday @OncoAlert @Uroweb @EAUYAUrology @EAU_YAUroTech @EauPatient @niklas_kluemper @onkowissen

Markus Eckstein

@Markuseckstein3

4 months

Today I will start a new small series: Uropathology for urologists and uro-oncologists. @urotoday @OncoAlert @imedverse Let us start with my favorite topic: Urothelial Cancer! You will often hear urothelial cancer is a heterogeneous disease, but why ?

6

21

123

1

22

36

Last Seen Profiles

@DalryPrimary

@jett78

@baerbockpress

@daniloproweb

@SilverbCinemas

@Astro1970

@BaumgratzPedro

@Babpravi

@JGSDF_YTS_X7

@AlbaParty

@eale_sbe

@woodmally1979

@Karl_Downey

@Jesuitsacfball

@Hannah08145009

@the_moon_lovers

@Br0keBassist

@Mazeppahorse

@CATISPRINTCESS

@kartofliska

@shinekjohn

@Iris_Descent_

@ToheedHuss67316

@MasonSoftball

@kerncountyfire

@humugofficial

@HiCommunities

@ChassiMusic

@SzupoTseng

@MelaninSunflowr

@chinalionfilm

@StAugustineTour

@HBortoloss80690

@stw_pdg

@SchiltzAline1

@wuyorbit

Markus Eckstein

@Markuseckstein3

1 month

We are happy to share our new study published today @JCO_ASCO (👉 ) on the role of NECTIN4 amplifications to predict responses to Enfortumab Vedotin treatment in metastatic urothelial cancer. With a huge contribution of our multinational team we uncovered

14

52

152

Markus Eckstein

@Markuseckstein3

4 months

Today I will start a new small series: Uropathology for urologists and uro-oncologists. @urotoday @OncoAlert @imedverse Let us start with my favorite topic: Urothelial Cancer! You will often hear urothelial cancer is a heterogeneous disease, but why ?

6

21

123

Markus Eckstein

@Markuseckstein3

3 months

It is incredible how fast the landscape of 🎯 targeted chemotherapies evolves🏄‍♂️. Antibody drug conjugates came to stay! ➡️ exciting times to study the tumor cellular surfaceome 🏄‍♂️ ‼️ ➡️ Multiple new predictive tests für ADCs will enter pathological testing soon opening a whole

0

36

98

Markus Eckstein

@Markuseckstein3

3 months

FGFR3 mutations are frequent alterations in urothelial cancer, but 🚨: ➡️ NMIBC: ~50% are mutated ➡️ MIBC: ~10% are mutated ➡️ UTUC stage independent: ~ 30% are mutated ➡️ mUC (=bc + UTUC): ~15-20 % are mutated Fusions are very rare throughout all entities! Frequency is ~1%‼️

5

30

81

Markus Eckstein

@Markuseckstein3

3 months

🚨🚨 EV-302 data finally published @NEJM ! Such a breakthrough for #metastatic #urothelial #cancer with doubling in OS and „insane ORR“. 👉 First #therapy improving OS massively by doubling overall survival of frontline metastatic patients‼️ 👉 All subgroups show huge benefits‼️

0

20

54

Markus Eckstein

@Markuseckstein3

2 months

Really honored that our paper has been selected as best translational paper published @EUplatinum #EAU24 ☺️. Highlights the importance of assessing biomarkers in the right tissue specimen especially for immune biomarkers 🎯. Thanks so much to all contributors @niklas_kluemper

5

7

52

Markus Eckstein

@Markuseckstein3

7 months

🔥Breaking News at #ESMO2023 !🔥 EV302 is changing the game, unbelievable data (HR=0.45!!!) for metastatic urothelial cancer patients, really an evolution #EV302 . Terrific presentation by @tompowles1 . 🙌🔬🎗️ @urotoday @OncoAlert @myESMO

0

18

51

Markus Eckstein

@Markuseckstein3

2 months

It‘been a while, but 🎉🔬 The 17th episode is out. The last entity we tackled was the „incarnation“ of hot/inflamed urothelial carcinomas🔥🔥🔥🔥 But what do you know about PD-L1 testing ? Today @MattGalsky presented important data of CheckMate274 at #EAU24 . PD-L1 positive

1

18

43

Markus Eckstein

@Markuseckstein3

8 months

🔬 After years of relentless dedication two incredible minds have achieved a major scientific award @dgukongress ! Their journey in testis and urothelial cancer research is a testament to the power of collaboration and perseverance. @niklas_kluemper @tim_nestler @urotoday

2

8

41

Markus Eckstein

@Markuseckstein3

3 months

Final results from #ASCENT in @JCO_ASCO . SG demonstrates huge OS benefits in patients with triple negative #breast #cancer . Although benefit present in all subgroups, there is an incremental benefit dependent on TROP2 surface expression 🏄‍♂️! 👉 another piece of the puzzle‼️🎯

3

17

40

Markus Eckstein

@Markuseckstein3

4 months

Really grateful to have the opportunity presenting our work at #GU24 !! Genomic protein related biomarkers might be good correlated for precise smart targeted chemotherapies! @ASCO @urotoday @OncoAlert @shilpaonc @drenriquegrande @PGrivasMDPhD @ViktorGruenwald

2

19

40

Markus Eckstein

@Markuseckstein3

2 months

🎉🔬 The 18th episode is out. Trastuzumab-Deruxtecan approved by FDA two days ago! Agnostic approval including bladder cancer 🚨‼️🎯 But only for Her2neu 3+ positive tumors! 👉 but what does 3+ actually mean? Similar to PD-L1 testing different assays and algorithms exist

2

12

39

Markus Eckstein

@Markuseckstein3

4 months

Our latest paper ist out in @Histo_Journal ! We comprehensively studied the membranous protein expression of the two important #ADC targets TROP2 and NECTIN4 (surfaceome 🏄‍♂️). it is the first paper on protein expression in a large cohort of over 200 muscle-invasive and metastic

2

15

39

Markus Eckstein

@Markuseckstein3

3 months

🎉🔬 The 13th episode is out. ➡️ What is the difference between nested and large nested urothelial carcinoma ? 🤓 ➡️Large 🪺🪺 nested urothelial carcinoma (LNUC) is a very particular subtype of #urothelial #cancer that is rare but biologically (🧬🧬) very interesting🏄‍♂️‼️ ➡️

3

13

33

Markus Eckstein

@Markuseckstein3

3 months

Really honored to receive this funding by @EKFStiftung ! It is a great opportunity to push our group‘s effort to develop novel (immunotherapy) approaches for #urothelial #cancer patients!

Else Kröner-Fresenius-Stiftung

@EKFStiftung

3 months

Else Kröner #Exzellenzstipendien an 8 herausragende #Medizinerinnen und #Mediziner vergeben – jeweils dotiert mit 350.000 Euro. ➡️ @BroeckelmannPJ , @markuseckstein3 , @JMustroph , @alexandernave , @jcpeeken

2

4

26

10

4

33

Markus Eckstein

@Markuseckstein3

3 months

Sacituzumab + Pembro is efficacious in metastic urothelial cancer following progress on platinum based chemotherapy !! Very interesting study by @PGrivasMDPhD and @y_loriot and team that unfortunately comes late. Is there still a place for this regimen after EV302 results ? But

1

16

30

Markus Eckstein

@Markuseckstein3

4 months

What is that? 🎉🔬 The 6th episode is out. @AmerUrological , @Uroweb , @OncoAlert @onkowissen @imedverse @Histo_Journal @niklas_kluemper

1

11

31

Markus Eckstein

@Markuseckstein3

2 months

Happy to share our commentary about EV-302 @EUplatinum @Uroweb - Thanks to @niklas_kluemper @ProfHadaschik @ViktorGruenwald Identification of patients with low or minimal chances of benefiting from EV/P is crucial, as there are other effective therapies available (eg,

0

7

29

Markus Eckstein

@Markuseckstein3

10 days

Long term update on he predictive value of MIBC response to NAC molecular subtypes presented by @djmcconkey at #AACRBladder @AACR . Some inconsistencies, but seems that certain luminal tumors respond better - but mixed with prognostic impacts as well - difficult. But clinical

0

5

27

Markus Eckstein

@Markuseckstein3

4 months

What is this ? @Uroweb @urotoday @OncoAlert @onkowissen @imedverse @niklas_kluemper @JAMANetwork @JAMA_current @ASCO

2

9

28

Markus Eckstein

@Markuseckstein3

1 year

Really grateful that @joostboormans highlighted our study on membranous NECTIN4 expression which is related to EV response/resistance published recently in @CCR_AACR @AACR . Rising Star @niklas_kluemper first author also gave a great presentation on #EAU2023 on the full abstract.

4

8

28

Markus Eckstein

@Markuseckstein3

3 months

What is that? 🎉🔬 The 8th episode is out. @AmerUrological , @Uroweb , @OncoAlert @onkowissen @imedverse @Histo_Journal @niklas_kluemper @urotoday

2

8

27

Markus Eckstein

@Markuseckstein3

2 years

Thank you @EUplatinum for highlighting our recently published paper on the predictive value of spatial immune microenvironment composition for immune checkpoint inhibition in metastatic urothelial cancer! Twittorial follows!

European Urology

@EUplatinum

2 years

Spatial Immunephenotypes of Distant Metastases but not Matched Primary UC Predict Response to ICI Erlmeier, @Markuseckstein3 et al "MET immunephenotypes & MHC-I status show potential to predict chemo & durable ICI responses, while PRIM TIME does not"

2

3

24

3

2

24

Markus Eckstein

@Markuseckstein3

3 months

🎉🔬 The 15th episode is out. 👉 Last Episode tackled FGFR3 testing #urothelial #cancer 👉 🚨🚨 But which tissue would you use/request for testing? 🚨🚨 👉Primary tumor ? 👉Metastatic Biopsy ? 👉Liquid Biopsy ? This is extremely important, maybe

Markus Eckstein

@Markuseckstein3

3 months

FGFR3 mutations are frequent alterations in urothelial cancer, but 🚨: ➡️ NMIBC: ~50% are mutated ➡️ MIBC: ~10% are mutated ➡️ UTUC stage independent: ~ 30% are mutated ➡️ mUC (=bc + UTUC): ~15-20 % are mutated Fusions are very rare throughout all entities! Frequency is ~1%‼️

5

30

81

1

17

24

Markus Eckstein

@Markuseckstein3

3 months

🎉🔬 The 16th episode is out. We are still in the middle of #subtype #urothelial #cancer histologies. 👉 what is the prime example of an inflamed UC with high checkpoint expression 🤓? 🔥🔥🔥🔥 👉 How would you call the histology below on the picture below ?

2

5

19

Markus Eckstein

@Markuseckstein3

2 months

@niklas_kluemper following @pcvblack giving a detailed overview on NECTIN-4 ADC development in urothelial cancer. Critical talk on the potential role of NECTIN4 being an important. Membranous expression is heterogenous among histologies and molecular subtypes (absent in basal

2

9

21

Markus Eckstein

@Markuseckstein3

4 months

In the first part we tried to understand the architecture of regular urothelium and key markers expressed in different layers of it. This important to understand why urothelial cancer can appear with multiple molecular and histological subtypes.

Markus Eckstein

@Markuseckstein3

4 months

Today I will start a new small series: Uropathology for urologists and uro-oncologists. @urotoday @OncoAlert @imedverse Let us start with my favorite topic: Urothelial Cancer! You will often hear urothelial cancer is a heterogeneous disease, but why ?

6

21

123

2

9

21

Markus Eckstein

@Markuseckstein3

4 months

Long Term results from PROFOUND out. Clearly showing the tremendous (🧪) predictive potential of deleterious BRCA alterations for PARP inhibitor Olaparib in metastatic castration resistant #prostatecancer !! Although certainly not powered for that: ‼️ germline BRCA patients tend

0

9

21

Markus Eckstein

@Markuseckstein3

7 months

Great final of #EMUC23 with @niklas_kluemper and Maurizio!! What a great experience/ game! Although 0:0 great game! @Ligue1UberEats

0

20

Markus Eckstein

@Markuseckstein3

4 months

Delighted for this highlighting by @EUplatinum @niklas_kluemper @AlexanderCoxMD @OncoAlert More to come soon !!

European Urology

@EUplatinum

4 months

Articles in Press: Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution @niklas_kluemper @JohannesStein9 @ChrisBolenz @roghmann @HolzelMichael @Markuseckstein3 #UroSoMe #Medtwitter

0

7

17

0

6

19

Markus Eckstein

@Markuseckstein3

2 months

Really nice paper demonstrating that tumor cell subtype lineages stay stable during metastatic evolution of upper urinary tract #urothelial #cancer ! Confirms our results from Cox et al, 2023 for bladder urothelial cancer Congrats Bishoy for this elegant

Dr. Bishoy M. Faltas

@FaltasLab

2 months

Excited to share our new paper just published @NatureComms @WCMGUcancer @WeillCornell Great collaboration between my lab with @ElementoLab @WCMEnglanderIPM and J.M. Mosquera @WCMCPathology 🔬 Full tweetorial below with more updates to come. Stay tuned!

17

41

212

0

7

20

Markus Eckstein

@Markuseckstein3

3 months

ctDNA profiling seems to have severe blind spots depending on metastasis location🤯. More pathogenic variants identified by tissue sequencing. 🧬🧪👉 What does this mean for targetable alterations? We likely miss some in ctDNA… @OncoAlert @imedverse @urotoday @niklas_kluemper

1

10

20

Markus Eckstein

@Markuseckstein3

1 year

Delighted to share our latest work on metastatic evolution of urothelial cancer molecular subtypes in @EUplatinum ! Superstars @AlexanderCoxMD @niklas_kluemper ! Congrats to this effort! Looking forward to great projects in the future with you and @IEO_HolzelLab @HolzelMichael

Alexander Cox

@AlexanderCoxMD

1 year

Very pleased to share our latest work: Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution published in @EUPlatinum - - @niklas_kluemper @markuseckstein3 . Follow our tweetorial about these clinically relevant data 1/9

2

12

32

1

5

20

Markus Eckstein

@Markuseckstein3

7 months

Great talk by @niklas_kluemper on the emerging role of NECTIN4 and related biomarkers to predict EV responses. Timely at background of groundbreaking EV302! Huge potential for true precision oncology with smart chemotherpies. @Uroweb @urotoday @OncoAlert #EMUC2023

1

2

20

Markus Eckstein

@Markuseckstein3

4 months

What is that? 🎉🔬 The 7th episode is out. @AmerUrological , @Uroweb , @OncoAlert @onkowissen @imedverse @Histo_Journal @niklas_kluemper @urotoday

5

6

19

Markus Eckstein

@Markuseckstein3

3 months

Really delighted that our novel pattern based grading approach for pT1 urothelial carcinomas is published @BJUIjournal ‼️ 👉 Growth and Invasive patterns 👉combined with tumor budding Outperform conventional grading systems and risk classification. 👉Assessment can be done via

BJU International

@BJUIjournal

3 months

A novel histological #grading approach to assess the aggressiveness of stage pT1 #BladderCancer provides improved risk stratification and predicts worse oncological outcomes. #NMIBC #budding #EAURiskGroup #pathology @Markuseckstein3 @UniFAU

0

12

35

3

10

19

Markus Eckstein

@Markuseckstein3

4 months

🎉🔬 The 3d episode of my Uropathology series tailored for Urologists & Oncologists is OUT NOW! Dive into the world of genitourinary cancers and enhance your expertise 🌟🩺 Featuring insights for @AmerUrological , @Uroweb , @ASCO , @PathSoc . Don't miss out! #Uropathology

Markus Eckstein

@Markuseckstein3

4 months

In the first part we tried to understand the architecture of regular urothelium and key markers expressed in different layers of it. This important to understand why urothelial cancer can appear with multiple molecular and histological subtypes.

2

9

21

1

3

18

Markus Eckstein

@Markuseckstein3

3 months

Final Results of POUT Trial out @ASCO #JCO ! Adjuvant platinum-based chemotherapy 🧪 increases disease free survival increase for upper urinary tract #urothelial #cancer patients, but not overall survival 🥲. However great study by Allison Birtle and group. Important message

1

6

17

Markus Eckstein

@Markuseckstein3

1 year

Congratulations @SiaLindskrog and @LDyrskjot ! Very important and elegant study on the single cellular composition of bladder cancer!

Sia Viborg Lindskrog

@SiaLindskrog

1 year

Time to rethink bulk tumor classification systems? Our work on intra-tumor subtype heterogeneity in bladder cancer using single-nucleus RNA-sequencing is now out in @EurUrolOpen : @LDyrskjot @SofieSchmoekel @IverNordentoft @moma_dk

0

16

50

1

0

15

Markus Eckstein

@Markuseckstein3

3 months

Great and critical Editorial @nejm by @GNiegisch praising a new hope for metastatic UC patients but also asking critical questions‼️ Read it here 👉 @niklas_kluemper @urotoday @PGrivasMDPhD @shilpaonc @OncoAlert @imedverse @drenriquegrande

Enfortumab Vedotin and Pembrolizumab — A New Perspective on Urothelial Cancer | NEJM

For several decades, platinum-based chemotherapy has been the standard first-line option for patients with advanced inoperable or metastatic (or both) urothelial carcinoma. This paradigm, in which ...

www.nejm.org

Markus Eckstein

@Markuseckstein3

3 months

🚨🚨 EV-302 data finally published @NEJM ! Such a breakthrough for #metastatic #urothelial #cancer with doubling in OS and „insane ORR“. 👉 First #therapy improving OS massively by doubling overall survival of frontline metastatic patients‼️ 👉 All subgroups show huge benefits‼️

0

20

54

1

4

15

Markus Eckstein

@Markuseckstein3

1 month

Cannot agree more ! ADCs need their target to bind -> no target no action. It is an exciting time for translational research in this field. Pathologists need to be involved as we will need to test for many indications soon likely! oncology! @Markuseckstein3 @PTarantinoMD

0

3

16

Markus Eckstein

@Markuseckstein3

4 months

We are looking for a motivated PhD student for exciting spatial transcriptomics projects in urothelial cancer! Our lab has been involved in important clinical and translational molecular UC research in the past years. PM if you are interested to join!

1

6

16

Markus Eckstein

@Markuseckstein3

7 months

Congrats Viktor!! Well deserved!

European Association of Urology (EAU)

@Uroweb

7 months

🏆 #EMUC23 Best Abstract Kidney Cancer: Prof. Viktor Grünwald (Essen, DE) Abstract: O12 - Tumor response by baseline metastases in patients with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial.

2

36

1

2

15

Markus Eckstein

@Markuseckstein3

1 year

Really delighted being a Ort of this great study just published @nature biomedical engineering. Congratulations @GuckLab @JochenGuck to this great success and looking forward to exciting projects in the future ! This methodology is exciting for rapid diagnosis on frozen sections!

GuckLab 🇺🇦

@GuckLab

1 year

Excited to share our latest paper in Nat Biomed Eng. With a #TissueGrinder we can dissociate biopsies and then use #RTDC and #AI to distinguish cancer from healthy tissue based on cell deformability and other physical parameters @MPZ_PhysMed @UniFAU

10

63

251

2

4

16

Markus Eckstein

@Markuseckstein3

7 months

Great study by @niklas_kluemper and @saal_jonas demonstrating that dynamic on treatment simple serum biomarker changes predict responses to immunotherapy in ccRCC! @urotoday @OncoAlert

UroToday.com

@urotoday

7 months

Integrating on-treatment modified Glasgow prognostic score and imaging to predict response and outcomes in metastatic #RenalCellCarcinoma . #BeyondTheAbstract with @niklas_kluemper @UniklinikBonn > @JAMAOnc

0

3

5

1

2

14

Markus Eckstein

@Markuseckstein3

5 months

These are truly fantastic results for patients with dMMR endometrial cancer. Another impressive proof of PD-1 inhibitors being especially effective in tumors with extremely high putstive neoantigen load and antigenicity @OncoAlert @niklas_kluemper

Toni Choueiri, MD

@DrChoueiri

5 months

In this phase 3 trial, the addition of #pembrolizumab to standard paclitaxel plus carboplatin chemotherapy in advanced #endometrial cancer resulted in 70% decrease in disease progression or death in #dMMR cohort. @NEJM @rne_md @aghajanc

1

20

103

0

5

13

Markus Eckstein

@Markuseckstein3

2 months

These data are so important !! That is a major breakthrough for MIBC patients in curative settings! @urotoday @niklas_kluemper @OncoAlert @imedverse @drenriquegrande @shilpaonc @PGrivasMDPhD

0

5

14

Markus Eckstein

@Markuseckstein3

1 year

Thank you @urotoday and @FaltasLab @WCMEnglanderIPM for selecting and discussing our latest paper about immune phenotype evolution during metastasierst progression of urothelial cancer and differential response to immunotherapy. @niklas_kluemper @IEO_HolzelLab @HolzelMichael .

UroToday.com

@urotoday

1 year

Understanding primary-metastatic immune phenotype discordance on urothelial cancer response to immune checkpoint inhibition. #ExpertCommentary @FaltasLab @WCMEnglanderIPM discusses work by Erlmeier et al. in @EUplatinum > @Markuseckstein3

0

1

11

1

4

13

Markus Eckstein

@Markuseckstein3

1 month

Thank you Liang for highlighting our story ! Great team effort and really looking forward validating it in the future ! 😊

Liang Cheng, MD

@LiangChengMD

1 month

Molecular Grading at Its Best! Take a look of this newly published paper @EurUrolOncol , led by @Markuseckstein3 . Great honor to be part of this study We proposed a novel, prognostically relevant, and biologically based scoring system for #bladdercancer

0

14

44

0

3

13

Markus Eckstein

@Markuseckstein3

4 months

🎉🔬 The 5th episode is out. @AmerUrological , @Uroweb , @ASCO , @PathSoc . #Uropathology #MedicalInnovation @NEJM @JAMANetwork @JAMA_current @OncoAlert @onkowissen @imedverse @Histo_Journal @niklas_kluemper MIBC has many facettes - major important topic is the right nomenclature

Markus Eckstein

@Markuseckstein3

4 months

🔬 the 4th episode is out: in this cast we are starting the topic of muscle-invasive #urothelial #muscle invasive #bladdercancer ! @niklas_kluemper @urotoday @imedverse @OncoAlert @Uroweb @onkowissen This post is just a short overview - there will be single post per topic! ‼️➡️

1

8

11

1

6

13

Markus Eckstein

@Markuseckstein3

3 months

🎉🔬 The 12th episode is out. After #divergent #histology in #urothelial #cancer we will now dive into specific #variant urothelial/urothelial #subtype histologies! ➡️ General overview on #variant #histology 👉9th episode! ➡️ 🪺 Nested subtype histology is very particular‼️

Markus Eckstein

@Markuseckstein3

3 months

🌶️🌡️Summary of my uropathology for urologists and oncologists series! 👉check it out! and retweet if you like! @urotoday @OncoAlert @Uroweb @EAUYAUrology @EAU_YAUroTech @EauPatient @niklas_kluemper @onkowissen

1

22

36

1

5

13

Markus Eckstein

@Markuseckstein3

10 days

@SiaLindskrog giving a great overview on NMIBC molecular subtype work that has been done in last decade(s) mainly driven by the Aarhus Group led by @LDyrskjot . It is fascinating how you and other groups moved this field to this stage! And great to hear that you are aiming for a

0

4

13

Markus Eckstein

@Markuseckstein3

2 years

Our new paper plates the role of FGFR3 alterations and its influence on BCG treatment of NMIBC is out now online first in European Urology. @EUplatinum

European Urology

@EUplatinum

2 years

Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non–muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy @Markuseckstein3 @mahadibaig

0

2

10

1

2

12

Markus Eckstein

@Markuseckstein3

3 months

Cool Study by @shilpaonc and @BenMironMD ! #ctDNA is really an interesting tool for molecular disease surveillance. Guess the major benefit will be molecular follow-up when ctDNA turns out to be reliable and sequencing becomes cheaper! #exciting #time ! Looking forward to seeing

Yüksel Ürün

@DrYukselUrun

3 months

New study: 🩸🧬🩸🧬Circulating tumor DNA (ctDNA) tumor fraction can predict survival in advanced bladder cancer patients! Higher ctDNA = worse outcome. Early detection & targeted treatment crucial. #BladderCancer #ctDNA #PrecisionMedicine @oncoalert @shilpaonc @BenMironMD

1

28

67

1

5

13

Markus Eckstein

@Markuseckstein3

2 months

Thanks for catching up @LambAlastair !

Alastair Lamb

@LambAlastair

2 months

@Markuseckstein3 provides elegant summary of #SpatialTranscriptomics / #SpatialProteomics in urology during #ESUR / #ESUP session #EAU24 . The age of molecular spatial pathology is here! Hypothesis-driven use of #Spatialomics should provide key 🔑 to unlocking tumour heterogeneity

0

3

17

0

3

13

Markus Eckstein

@Markuseckstein3

7 months

Was a pleasure to contribute to the session!

Imran Ahmad

@ahmadurology

7 months

Great session on the advances in spatial transcriptomics in urogenital cancer. How to find the lethal clone? @LambAlastair @Tom_J_Mitchell @Markuseckstein3 #ESUR23 @Uroweb

0

3

20

0

2

11

Markus Eckstein

@Markuseckstein3

4 months

The urothelium consists of three different layers: 1) Basal cell layer: cells that express markers like CK5, CD44, but not GATA3 or FOXA1 2) Intermediate cell layer: differentiated cells that express CK7 (cytokeratin found in glandular epithelium!!!), GATA3, FOXA1 and PPARG.

1

12

Markus Eckstein

@Markuseckstein3

2 months

If you want to learn more about PD-L1 testing and that not the antibodies or assays are the problem, but the scoring algorithms read here 👉 @DrYukselUrun @amerseburger @urotoday @OncoAlert #pathtwitter @PGrivasMDPhD @shilpaonc @niklas_kluemper

Yüksel Ürün

@DrYukselUrun

2 months

We have a PDL-1 assessment method where there are many different antibodies and the methodology does not match exactly. Moreover, we see significant inconsistencies between studies of the same drug on different tumors, or studies of different drugs on the same tumor. In this

4

7

26

3

5

12

Markus Eckstein

@Markuseckstein3

4 months

Should we reconsider Gleason 3 as non cancer growth pattern ? Interesting survey results @EurUrolFocus ! what do you think about that? @Uroweb @niklas_kluemper @Uromigos @urotoday @imedverse @OncoAlert @ASCO Personally I am ambivalent: ➡️ Gleason 3 is an invasive carcinoma by

Eur Urol Focus

@EurUrolFocus

4 months

Physician Perception of Grade Group 1 Prostate Cancer @Saouduro @laen120er @GladellPaner @aleberlin2 @dr_coops @uroegg #UroSoMe #Medtwitter #ProstateCancer

1

5

7

2

5

11

Markus Eckstein

@Markuseckstein3

3 months

This is actually a very important study showing that we are not there yet with molecular urothelial cancer subtypes yet 🧬🔬🧬! A lot to figure out until we can use this in clinical practice 🤯! @GottfridSjodahl @niklas_kluemper @DrYukselUrun @PGrivasMDPhD @shilpaonc @OncoAlert

European Urology

@EUplatinum

3 months

Throwback Thursday: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes @GottfridSjodahl @UroLiedberg

0

12

33

1

6

12

Markus Eckstein

@Markuseckstein3

10 days

@SaraEWobker kicking off #AACRBladder @AACR on day 1 with a comprehensive overview on urothelial cancer histology including divergent and subtype histology. Important topic that cannot be reacted often enough - especially to arise awareness for the biological and clinical

0

3

12

Markus Eckstein

@Markuseckstein3

7 months

🚨 The abstract of EV302 is out, showing a groundbreaking 31.5 vs 16.1 months. A revolutionary SOC is on the horizon for metastatic urothelial cancer patients @myESMO ! 📊 curious on biomarkers. #CancerResearch #UrothelialCancer #ESMO23 🌐 @urotoday @niklas_kluemper

Jonathan Rosenberg MD

@DrRosenbergMSK

7 months

EV302 abstract: EV/pembro improves OS to 31.5 months c/w 16.1 months for chemo. Looking forward to seeing the data but this is transformative for the field and will change the standard of care. @MSKCancerCenter @tompowles1 @BladderCancerUS @MattGalsky @apolo_andrea

4

63

202

0

2

11

Markus Eckstein

@Markuseckstein3

1 year

Really important study by @DanNett1980 ! Congratulations and thank you for involving me. Car-T-cells are a promising new therapeutic concept not only for liquid neoplasms. Really excited to see further data on their efficacy against urological neoplasms.

Daniel Nettersheim 🧬

@DanNett1980

1 year

Targeting CD24 by NK-CAR cells in urological malignancies seems very promising...read our latest article (pre-final proof) published recently @FEBSJournal ! @UniklinikDUS @HHU_de @MedHHU @DGUrologie @MaGIC_GCT #urology #cancer #immunotherapy

1

4

10

0

2

11

Markus Eckstein

@Markuseckstein3

1 month

Happy to share a collaborative work where I was involved as „immunopathologist“ @NatureMedicine ! Beside my oncology hobby we provide services for tissue monitoring therapy responses to autoimmune diseases. Led by @grieshaber and Georg Schett our study shows 👉 that

0

2

10

Markus Eckstein

@Markuseckstein3

3 months

Path residents trying to prepare for Board certifications… realizing there are 15 books to go 😂🏄‍♂️🤯.

0

2

11

Markus Eckstein

@Markuseckstein3

4 months

🔬 the 4th episode is out: in this cast we are starting the topic of muscle-invasive #urothelial #muscle invasive #bladdercancer ! @niklas_kluemper @urotoday @imedverse @OncoAlert @Uroweb @onkowissen This post is just a short overview - there will be single post per topic! ‼️➡️

Markus Eckstein

@Markuseckstein3

4 months

🎉🔬 The 3d episode of my Uropathology series tailored for Urologists & Oncologists is OUT NOW! Dive into the world of genitourinary cancers and enhance your expertise 🌟🩺 Featuring insights for @AmerUrological , @Uroweb , @ASCO , @PathSoc . Don't miss out! #Uropathology

1

3

18

1

8

11

Markus Eckstein

@Markuseckstein3

4 months

Really nice to see that there is growing interest in deep profiling of penile cancer - a hard treat aggressive cancer entity that has been widely neglected in the last decades ! @OncoAlert @ASCO @urotoday #GU24

Laura Elst

@ElstLaura

4 months

Excited to unveil the biological landscape of penile cancer at @ASCO #GU24 . Stop by poster board E7 for a journey into the penile cancer single-cell RNA sequencing wonderland 🧬🔬 Big shoutout to @MaartenAlbersen for all the guidance 🙏🏼

5

8

69

0

3

10

Markus Eckstein

@Markuseckstein3

3 months

Last generation sequencing 🤓 - Sanger Sequencing: Do not underestimate these techniques🚨 they are ancient but very powerful! Nothing beats Sanger sequencing sensitivity‼️ 👉 there is a nice snapshot multiplex PCR approach for FGFR3 (see below). Advantage: 👉 Highly

1

2

10

Markus Eckstein

@Markuseckstein3

7 months

Great initial data for NMIBC patients, targeted therapy hitting its prime target! Maybe the first game changer in this field for decades, really looking forward to future data in expansion trials. @urotoday @OncoAlert @myESMO #ESMO23 #bladdercancer @roghmann

Sabine D. Brookman-May

@brookmans76

7 months

#ESMO23 First results of #TAR210 🥨 in patients with #NMIBC 👉 Promising efficacy data: ➡️ High recurrence free/complete response rate: 82% and 87% ➡️ 11/13 evaluable patients (BCG exp. HR #NMIBC ) + 13/15 (IR #NMIBC ) recurrence free #AntoniVilaseca @JanssenGlobal

1

22

48

0

3

11

Markus Eckstein

@Markuseckstein3

1 year

We are extremely grateful for our new collaborative grant by the IZKF Erlangen to study chemotherapy and immunotherapy resistance together with @Engel_FB_Lab ! Two PhD positions are open!

EngelLab

@Engel_FB_Lab

1 year

The Engel lab is highly grateful for new funding by the IZKF (interdisciplinary center for clinical research) Erlangen for studying #ferroptosis and chemo-/immunotherapy resistance in #urothelial carcinoma in collaboration with @Markuseckstein3 (two PhD positions).

3

0

14

1

2

11

Markus Eckstein

@Markuseckstein3

4 months

United States cancer statistics just put today ! @OncoAlert @niklas_kluemper Bladder cancer remains a stable constant in male cancer patients.

Toni Choueiri, MD

@DrChoueiri

4 months

JUST IN: Most cited paper every year in Cancer is out: Cancer statistics, 2024 in @CACancerJournal @AmericanCancer @OncoAlert @AmerCancerCEO

3

113

283

0

3

11

Markus Eckstein

@Markuseckstein3

2 years

Thanks @urotoday for highlighting our article on CRP kinetics predicting response to immune checkpoint inhibitor treatment of patients with metastatic urothelial cancer!

UroToday.com

@urotoday

2 years

C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic #UrothelialCarcinoma . #BeyondTheAbstract with @niklas_kluemper @UniklinikBonn and @Markuseckstein3 @UniFAU > #EJC @IEO_HolzelLab @IEO_Bonn

0

2

9

2

3

10

Markus Eckstein

@Markuseckstein3

8 months

Exploring the profound implications of pinpointing ADC targets across a multicancer landscape, this study sheds light on novel therapeutic pathways and target expression of #ADCtargets . Highly valuable pper for an exciting era of #precisiononcology . #CancerResearch .

Niklas Klümper

@niklas_kluemper

8 months

Great paper by Bosi et al: Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response🎯Co-expression of various ADC targets (e.g. NECTIN4) again highlights potential for agnostic ADC therapy @OncoAlert @urotoday

1

8

36

0

2

11

Markus Eckstein

@Markuseckstein3

1 year

@MattGalsky @JohnEbbenMDPhD @JonAnker1 @TumorBoardTues @IntegrityCE @AstraZeneca @tarekmd91 @michelle_a_tran @kai_tsao @GeneticsRach @sonpavde @roula_almufti @JLVasquez82 @MichalisLiontos @alirezaghoreifi @montypal @PGrivasMDPhD @FDA @danielkeizman @OncoBellmunt @EnriqueGallar12 @TanyaAneichyk @MichaelJSlade @pjhensley11 @dinowhassan @tompowles1 @drenriquegrande @amerseburger @dratozsin @KKBree @Hoomandjaladat @cnsternberg @DanielPetrylak @dralvaropinto @shilpaonc @brian_rini @apolo_andrea Clear as mud is great !! But isn’t only the algorithm, but also that the microenvironment is bigger than PD-L1, that the immune contexture matters and that we are often testing the wrong material (archived tissue, primary tumors)!

Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas...

The tumor immune microenvironment (TIME) is subject to considerable dynamics during metastatic progression. TIME assessment on pretherapeutic biopsied distant metastases shows promising potential for...

www.europeanurology.com

1

3

11

Markus Eckstein

@Markuseckstein3

3 months

🎉🔬 The 9th episode is out. ➡️ Checkout for summary of all episodes🧪🔬‼️ Last episodes tackled #divergent #histology in #urothelial #cancer . ➡️ But what is Variant or now Subtype Histology ? ➡️ Why is this difference important? @AmerUrological ,

Markus Eckstein

@Markuseckstein3

3 months

🌶️🌡️Summary of my uropathology for urologists and oncologists series! 👉check it out! and retweet if you like! @urotoday @OncoAlert @Uroweb @EAUYAUrology @EAU_YAUroTech @EauPatient @niklas_kluemper @onkowissen

1

22

36

1

5

9

Markus Eckstein

@Markuseckstein3

3 months

Really nice results from the Rotterdam Team @AlbertoNakauma @NatureComms ! Confirms the results we published 2023 in @EUplatinum ➡️ Thank you for also confirming that METASTATIC tissue samples are highly predictive for immunetherapy. Another hint for poor

Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas...

The tumor immune microenvironment (TIME) is subject to considerable dynamics during metastatic progression. TIME assessment on pretherapeutic biopsied distant metastases shows promising potential for...

www.europeanurology.com

Alberto Nakauma

@AlbertoNakauma

3 months

1) Check out our newest publication in Nature Communications: “Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer”

3

6

16

0

3

10

Markus Eckstein

@Markuseckstein3

4 months

New short correspondence out @JAMAOnc by @montypal and team. Astonishing ORR for metastatic #prostatecancer with TMB >=10 Mut/mb. Mutation rates are however in stark contrast to much larger series reported before in mCRPC! (>95% of PC with TMB <1-2 Mut/mb). What is the MSI

0

2

9

Markus Eckstein

@Markuseckstein3

3 months

Next episode will tackle the question which tissue should be tested for FGFR3 alterations! 👉 this is a matter of discussion and very important🚨

0

10

Markus Eckstein

@Markuseckstein3

3 months

Liquid biopsies: In principle these assays are ultra deep NGS sequencing assays, so see ☝️! ➡️ Careful: Liquid biopsies are often hyped by oncologists, but have severe limitations! ➡️ Liquid biopsies have severe blind spots, especially if tumors are not shedding ctDNA to the

1

2

10

Markus Eckstein

@Markuseckstein3

3 months

This was thought as episode 14 ;-) the epilogue is missing: 🎉🔬 The 14th episode is out. 👉 Last Episode was on large nested urothelial cancer, the prototype of fgfr3 mutant #urothelial #cancer 👉Thus here an excursion to FGFR3 testing which very important as Erdafitinib -

Markus Eckstein

@Markuseckstein3

3 months

FGFR3 mutations are frequent alterations in urothelial cancer, but 🚨: ➡️ NMIBC: ~50% are mutated ➡️ MIBC: ~10% are mutated ➡️ UTUC stage independent: ~ 30% are mutated ➡️ mUC (=bc + UTUC): ~15-20 % are mutated Fusions are very rare throughout all entities! Frequency is ~1%‼️

5

30

81

0

4

10

Markus Eckstein

@Markuseckstein3

1 year

Now also online our back-to-back story on metastatic evolution of thereputic targets in metastatic urothelial cancer ! @niklas_kluemper @IEO_HolzelLab @IEO_Bonn @damian_ralser @HolzelMichael @UniFAU

Markus Eckstein

@Markuseckstein3

2 years

Thank you @EUplatinum for highlighting our recently published paper on the predictive value of spatial immune microenvironment composition for immune checkpoint inhibition in metastatic urothelial cancer! Twittorial follows!

3

2

24

1

5

9

Markus Eckstein

@Markuseckstein3

4 months

Studying metastatic biology rather than primary site biology (eg archival tissue) is urgently needed. But different tumors will remain different at metastatic sites based on their primary site traits. Primary biology and evolution drives metastasis not the host organ!

Niklas Klümper

@niklas_kluemper

4 months

Great perspective from @FAndreMD & @BenjaminBesseMD @Nature : The community urgently needs to shift from using organ-based classifications of cancer to using molecular-based ones -> Tumor-agnostic targeted therapies (e.g. ADC) will be important for rapid implementation @OncoAlert

0

1

9

0

2

10

Markus Eckstein

@Markuseckstein3

7 months

Great summary of urothelial cancer highlights at ESMO! @sonpavde ! Exciting times for urothelial cancer patients and their families. Hope that similar breakthroughs will be seen for early stages (curative settings)! Also time for precise biomarkers ! @urotoday @OncoAlert

Guru P. Sonpavde, MD

@sonpavde

7 months

#ESMO2023 - #bladdercancer #urothelialcarcinoma highlights: EV302, CHECKMATE901, THOR, DAD- @BradMcG04 & I discuss practical implications of the data in advanced disease @GUOncologyNow @Uromigos @BladderCancerUS -1) EV+pembro has a practice-changing impact in both

1

13

37

0

1

10

Markus Eckstein

@Markuseckstein3

1 year

Happy to share our latest work: Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance @CCR_AACR … @niklas_kluemper @HolzelMichael @IEO_HolzelLab @IEO_Bonn

Clinical Cancer Research | American Association for Cancer Research

aacrjournals.org

Niklas Klümper

@niklas_kluemper

1 year

Happy to share our work: Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance @CCR_AACR Follow our tweetorial about this clinically important data 1/12

7

36

119

2

9

Markus Eckstein

@Markuseckstein3

6 months

Cannot agree more! Aiming without a target being present does not make biological sense! We need detailed analyses of clinical trials to learn which patients are really responding based on target protein expression. Everything else is contradictory to precision medicine!

Niklas Klümper

@niklas_kluemper

6 months

HER2 heterogeneity is important for HER2-ADC response. ADC response depends on its target gene expression🎯 EV response depends on NECTIN4 (PMID: 36534531) but heterogeneous NECTIN4 in mUC has not yet been systematically investigated! @OncoAlert @urotoday

1

13

53

0

1

9

Markus Eckstein

@Markuseckstein3

1 month

@niklas_kluemper

Enrique Grande

@drenriquegrande

1 month

⚡️ NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer #BladderCancer #Immunology @Markuseckstein3 @JCO_ASCO

2

18

71

1

3

9

Markus Eckstein

@Markuseckstein3

4 months

Take Home: ➡️ TROP2 widely expressed on cell membranes of UC except neuroendocrine and sarcomatoid! ➡️ NECTIN4 membranous expression is heterogenous and clearly linked to luminal UC! Low or negative on membranes in Basal squamous‼️ ➡️Membranous NECTIN4 protein expression

0

3

9

Markus Eckstein

@Markuseckstein3

3 months

The companion diagnostic assay approved for FGFR3 alteration detection in conjunction with Erdafitinib is the Therascreen assay from Quiagen: ➡️ This assay requires RNA‼️ from FFPE or liquid biopsies‼️ ➡️ … and detects mutation or fusion specific transcripts via a RT-qPCR‼️ ➡️

1

3

8

Markus Eckstein

@Markuseckstein3

1 month

Thanks for posting @PTarantinoMD !!

Paolo Tarantino

@PTarantinoMD

1 month

Great work by @niklas_kluemper et al. finding that 24% of mUC have Nectin4 ampl, which predicts ⬆️ORR (96% vs 32%) & ⬆️OS with the ADC #EV . Excited to see EV data for MBC presented at ASCO by @antgiorda & to study this biomarker in breast cancer. Congrats!

2

17

52

0

1

9

Markus Eckstein

@Markuseckstein3

2 months

Congrats !!

Clémentine Le Magnen

@ClemLeMagnen

2 months

Thanks @Uroweb for a great #EAU24 meeting! Proud that our work on a #bladdercancer patient-derived #organoid biobank was awarded 3rd prize best oncology abstract 🥉! Congrats to the two first-authors @Michele_Garioni and Viviane Tschan ⭐️

2

28

1

2

9

Markus Eckstein

@Markuseckstein3

2 months

Cannot agree more, great news for patients with no more therapy options but high expression of Her2neu! This is an important approval, which is expanding the landscape of ADCs🎯. Exciting times, and more precise biomarker work for us pathologists ! @AmerUrological , @Uroweb ,

Niklas Klümper

@niklas_kluemper

2 months

Great news again! First agnostic ADC approval for anti HER2 #TDXd based on DESTINY-PanTumor02! @US_FDA Approval based on HER2-biomarker-selection, only HER2 IHC3+ solid tumors with no satisfactory alternative treatment options -> ADC targetability matters! Great news for

2

6

16

0

2

9

Markus Eckstein

@Markuseckstein3

2 months

Don’t miss out to hear @niklas_kluemper !! ADCs are hot ! 🔥

0

1

9

Markus Eckstein

@Markuseckstein3

4 months

These data are huge for RCC patients. Long-term plateau really underlines the role of Nivo IPI as current SOC. It would be so nice to see pathological (eg sarcomatoid histology) and biomarker subgroup analysis!! #GU24 @ASCO @urotoday @OncoAlert

UroToday.com

@urotoday

4 months

Nivolumab + ipilimumab vs sunitinib for first-line treatment of advanced #RCC : long-term follow-up data from the phase 3 #CheckMate214 trial. Presented by Nizar Tannir, MD, FACP @MDAndersonNews . #GU24 written coverage by @zklaassen_md @GACancerCenter >

0

4

5

0

2

9

Markus Eckstein

@Markuseckstein3

1 year

Congrats Niklas ! Very well deserved!! 🎉

Uniklinik Bonn

@UniklinikBonn

1 year

Ein Schritt Richtung Präzisionsonkologie - @niklas_kluemper , Urologe des #ukbonn , erhält renommierten C. E. Alken Preis für wissenschaftliche Erkenntnisse zu neuem Krebsmedikament. Cc. @CCR_AACR @Markuseckstein3 @damian_ralser @HolzelMichael @IEO_HolzelLab

0

21

1

0

9

Markus Eckstein

@Markuseckstein3

1 month

🔎 Conclusion NECTIN4 amplifications serve as effective genomic predictors for both EV response and long-term survival in mUC patients. 🧐 Significance This finding could guide personalized treatment strategies in mUC patients and potentially other cancers with NECTIN4

2

3

8

Markus Eckstein

@Markuseckstein3

4 years

Our latest paper ab predicting survival of muscle invasive urothelial Cancer patients after curative cystectomy and adjuvant chemotherapy based on a cytotoxic T-cell related gene expression signature just went online today in JITC! Thanks to all contributors, a great effort!

Journal for ImmunoTherapy of Cancer

@jitcancer

4 years

New #JITC article: Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy @Markuseckstein3

0

5

0

7

Markus Eckstein

@Markuseckstein3

4 months

🎉🔬 The 2nd episode of my Uropathology series tailored for Urologists & Oncologists is OUT NOW! Dive into the world of Genitourinary pathology and enhance your expertise 🌟🩺 Featuring insights for @AmerUrological , @Uroweb , @ASCO , @PathSoc . Don't miss out! #Uropathology

Markus Eckstein

@Markuseckstein3

4 months

In the first part we tried to understand the architecture of regular urothelium and key markers expressed in different layers of it. This important to understand why urothelial cancer can appear with multiple molecular and histological subtypes.

2

9

21

0

2

8

Markus Eckstein

@Markuseckstein3

4 months

Urothelial cancer is considered to arise from the urothelium of the renal pelvis, the ureter, the urinary bladder and the urethra. Importantly, urothelium is a specialized epithelium that has both features of glandular and squamous epithelium!

1

8

Markus Eckstein

@Markuseckstein3

1 month

📊 Results High Frequency: NECTIN4 amplifications frequent in bladder cancer (17% in TCGA data; 26% in study cohorts). Positive Response: 96% objective response rate in mUC-EV patients with NECTIN4 amplifications versus 32% in those without. Survival Benefit: NECTIN4

1

2

8